Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.36 |
| ▸ | POLB | P06746 | 1/20 | 0.36 |
| ▸ | DGAT1 | O75907 | 1/20 | 0.33 |
| ▸ | PKM | P14618 | 1/20 | 0.32 |
| ▸ | KEAP1 | Q14145 | 1/20 | 0.31 |
| ▸ | NFE2L2 | Q16236 | 1/20 | 0.31 |
| ▸ | HCAR2 | Q8TDS4 | 1/20 | 0.31 |
| ▸ | TSHR | P16473 | 1/20 | 0.31 |
| ▸ | KCNN4 | O15554 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL28714306 | 0.77 | DGAT1 (0.40) | DGAT1PKM | |
| SCHEMBL8446819 | 0.74 | DGAT1 (0.37) | ALDH1A1POLBDGAT1PKMTSHR | |
| SCHEMBL27608767 | 0.73 | ALDH1A1 (0.38) | ALDH1A1POLBDGAT1PKMTSHR | |
| SCHEMBL4706953 | 0.72 | MEN1 (0.33) | ALDH1A1TSHR | |
| SCHEMBL29963438 | 0.72 | ALDH1A1 (0.33) | ALDH1A1 | |
| SCHEMBL809243 | 0.71 | DGAT1 (0.40) | ALDH1A1POLBDGAT1PKMTSHR | |
| SCHEMBL32680313 | 0.70 | TDP1 (0.32) | ALDH1A1TSHR | |
| SCHEMBL27746607 | 0.70 | ALOX15 (0.31) | — | |
| SCHEMBL29674742 | 0.69 | DGAT1 (0.39) | ALDH1A1POLBDGAT1PKMTSHR | |
| SCHEMBL2477744 | 0.69 | CYP4F2 (0.39) | ALDH1A1POLBDGAT1PKMKEAP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1856110-B1 | OXYINDOLE DERIVATIVES AS 5HT4 RECEPTOR AGONISTS | PFIZER (US) | 2011-06-22 | — | — | EP | disclosed |
| US-20100173925-A1 | OXYINDOLE DERIVATIVES | PFIZER INC | 2010-07-08 | — | — | US | disclosed |
| US-7737163-B2 | Benzimidazolone carboxylic acid derivatives | PFIZER INC. (US) | 2010-06-15 | — | — | US | disclosed |
| US-7705020-B2 | Benzimidazolone carboxylic acid derivatives | PFIZER INC. (US) | 2010-04-27 | — | — | US | disclosed |
| US-7595329-B2 | Benzimidazolone carboxylic acid derivatives | PFIZER INC (US) | 2009-09-29 | — | — | US | disclosed |
| US-7589109-B2 | Oxyindole derivatives | PFIZER INC (US) | 2009-09-15 | — | — | US | disclosed |
| US-20080108660-A1 | Benzimidazolone Carboxylic Acid Derivatives | PFIZER INC | 2008-05-08 | — | — | US | disclosed |
| EP-1856110-A1 | OXYINDOLE DERIVATIVES AS 5HT4 RECEPTOR AGONISTS | Pfizer, Inc. (US) | 2007-11-21 | — | — | EP | disclosed |
| EP-1758891-A2 | BENZIMIDAZOLONE CARBOXYLIC ACID DERIVATIVES | Pfizer Japan Inc. (JP) | 2007-03-07 | — | — | EP | disclosed |
| US-20060194842-A1 | Oxyindole derivatives | PFIZER INC. | 2006-08-31 | — | — | US | disclosed |
| WO-2006090279-A1 | OXYINDOLE DERIVATIVES AS 5HT4 RECEPTOR AGONISTS | PFIZER JAPAN INC. (JP) | 2006-08-31 | — | — | WO | disclosed |
| WO-2005123718-A2 | BENZIMIDAZOLONE CARBOXYLIC ACID DERIVATIVES | PFIZER JAPAN INC. (JP) | 2005-12-29 | — | — | WO | disclosed |
| US-20050277671-A1 | Benzimidazolone carboxylic acid derivatives | PFIZER INC | 2005-12-15 | — | — | US | disclosed |
| US-20050277672-A1 | Benzimidazolone carboxylic acid derivatives | PFIZER INC | 2005-12-15 | — | — | US | disclosed |
| US-20050277673-A1 | Benzimidazolone carboxylic acid derivatives | PFIZER JAPAN INC. (JP) | 2005-12-15 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100173925-A1 | OXYINDOLE DERIVATIVES | HTR4, HTR5A, HRH4 | ALDH1A1 2553/4885POLB 4788/4885DGAT1 2695/4885 |
| US-20050277673-A1 | Benzimidazolone carboxylic acid derivatives | HRH2, HRH4, GPR4 | ALDH1A1 1109/4885POLB 4221/4885DGAT1 4189/4885 |
| US-20050277672-A1 | Benzimidazolone carboxylic acid derivatives | HRH2, HRH4, GPR4 | ALDH1A1 1109/4885POLB 4221/4885DGAT1 4189/4885 |
| US-20060194842-A1 | Oxyindole derivatives | HTR4, HTR5A, HRH4 | ALDH1A1 2553/4885POLB 4788/4885DGAT1 2695/4885 |
| US-20050277671-A1 | Benzimidazolone carboxylic acid derivatives | HRH2, HRH4, GPR4 | ALDH1A1 1109/4885POLB 4221/4885DGAT1 4189/4885 |
| US-20080108660-A1 | Benzimidazolone Carboxylic Acid Derivatives | HRH2, HRH4, GPR4 | ALDH1A1 1018/4885POLB 4325/4885DGAT1 4217/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.